Linked Life Data

17290345

Source:http://linkedlifedata.com/resource/pubmed/id/17290345

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2007-2-9
pubmed:abstractText
A panel of markers, selected for the suspected bladder cancer relevance of their corresponding genes, were explored for their expression and subcellular location in urinary bladder tissue. The expression in normal urothelium, in non-metastasised transitional cell carcinomas (TCC), and in primary metastasised TCC with corresponding metastases was mapped. Potential associations between the proteins were identified. The observations were then combined in a set of hypotheses aimed at further hypothesis testing. Membranous ERBB4 and cytoplasmic p21RAS were downregulated in carcinoma cells compared with normal urothelium cells. FGFR3 was translocated from the cytoplasm to the nucleus. ERBB2 was translocated to the membrane and seemingly upregulated in one subgroup and conversely downregulated in another. EGFR, KAI1 and possibly PTEN revealed increased membranous immunoreactivity in non-metastasised tumours. The metastases showed decreased nuclear FGFR3 and membranous PTEN staining compared with corresponding primary tumours. EGFR expression was positively correlated with the expression of PTEN and FGFR3. The expression of ERBB2 was negatively correlated with p21RAS expression. According to our results, bladder carcinogenesis comprises FGFR3 translocation to the nucleus, upregulation of EGFR, ERBB2, KAI1 and PTEN; downregulation of p21RAS; and translocation of EGFR, ERBB2, and possibly PTEN to the membrane. Our results support the hypotheses regarding PTEN and KAI1 functioning as tumour suppressors in bladder cancer. EGFR and KAI1 may discriminate between non-metastasised and metastasised cancers. A complex network of associations between the factors is suggested.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1699-5848
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
349-63
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:17290345-Adenocarcinoma, pubmed-meshheading:17290345-Adolescent, pubmed-meshheading:17290345-Adult, pubmed-meshheading:17290345-Aged, pubmed-meshheading:17290345-Aged, 80 and over, pubmed-meshheading:17290345-Antigens, CD82, pubmed-meshheading:17290345-Combined Modality Therapy, pubmed-meshheading:17290345-Female, pubmed-meshheading:17290345-Humans, pubmed-meshheading:17290345-Immunoenzyme Techniques, pubmed-meshheading:17290345-Male, pubmed-meshheading:17290345-Middle Aged, pubmed-meshheading:17290345-Neoplasm Proteins, pubmed-meshheading:17290345-Oncogene Protein p21(ras), pubmed-meshheading:17290345-PTEN Phosphohydrolase, pubmed-meshheading:17290345-Receptor, Epidermal Growth Factor, pubmed-meshheading:17290345-Receptor, Fibroblast Growth Factor, Type 3, pubmed-meshheading:17290345-Receptor, erbB-2, pubmed-meshheading:17290345-Tissue Array Analysis, pubmed-meshheading:17290345-Tumor Markers, Biological, pubmed-meshheading:17290345-Urinary Bladder Neoplasms, pubmed-meshheading:17290345-Urothelium
pubmed:year
2007
pubmed:articleTitle
Protein networking in bladder cancer: immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium.
pubmed:affiliation
The Urological Research Institute, Oslo Urological University Clinic, Aker University Hospital, Oslo, Norway. ranveig.rotterud@medisin.uio.no
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't